Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses

Hedvig Glans 1,2*, Sara Gredmark-Russ 1,3, Mikaela Olausson 4, Sara Falck-Jones 5,6, Renata Varnaite 3, Wanda Christ 3, Kimia T. Maleki 3,4, Maria Lind Karlberg 4, Sandra Broddesson 4,7, Ryan Falck-Jones 8,9, Max Bell 8,9, Niclas Johansson 1,2, Anna Färnert 1,2, Anna Smed-Sörensen 5,6, Jonas Klingström 3,4 and Andreas Bråve 4

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The understanding of the transmission and the duration of viral shedding in SARS-CoV-2 infection is still limited.

Objectives: To assess the timeframe and potential risk of SARS-CoV-2 transmission from hospitalized COVID-19 patients in relation to antibody response.

Method: We performed a cross-sectional study of 36 COVID-19 patients hospitalized at Karolinska University Hospital. Patients with more than 8 days of symptom duration were sampled from airways, for PCR analysis of SARS-CoV-2 RNA and in vitro culture of replicating virus. Serum SARS-CoV-2-specific immunoglobulin G (IgG) and neutralizing antibodies titers were assessed by immunofluorescence assay (IFA) and microneutralization assay.

Results: SARS-CoV-2 RNA was detected in airway samples in 23 patients (symptom duration median 15 days, range 9–53 days), whereas 13 patients were SARS-CoV-2 RNA negative (symptom duration median 21 days, range 10–37 days). Replicating virus was detected in samples from 4 patients at 9–16 days. All but two patients had detectable levels of SARS-CoV-2-specific IgG in serum, and SARS-CoV-2 neutralizing antibodies were detected in 33 out of 36 patients. Total SARS-CoV-2-specific IgG titers and neutralizing antibody titers were positively correlated. High levels of both total IgG and neutralizing antibody titers were observed in patients sampled later after symptom onset and in patients where replicating virus could not be detected.

Conclusions: Our data suggest that the presence of SARS-CoV-2 specific antibodies in serum may indicate a lower risk of shedding infectious SARS-CoV-2 by hospitalized COVID-19 patients.

Keywords: COVID-19, SARS-CoV-2, Viral shedding, Culture, Antibodies

* Correspondence: hedvig.glans@ki.se
1Department of Infectious Diseases, Karolinska University Hospital, SE-141 86 Stockholm, Sweden
2Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
By the end of December 2019, a cluster of severe pneumonia cases of unknown origin were reported from Wuhan, Hubei province, China [1]. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified and isolated on 7 January 2020 [2], causing the coronavirus disease 2019 (COVID-19) [3]. Today, COVID-19 is a pandemic with significant impact on morbidity and mortality around the world [4].

A better understanding of the transmission, the duration of viral shedding and the dynamics of serological responses is of importance to limit the spread of SARS-CoV-2. Detection of viral ribonucleic acid (RNA) in patients may indicate a risk for spread of the virus, and can be used as a marker to guide recommendations of isolation of potentially infectious patients. SARS-CoV-2 RNA has been detected in the airways of COVID-19-patients over the course of disease, normally up to 12–20 days, but in severe cases for longer periods of time [5–8]. Moreover, SARS-CoV-2 RNA has been detected up to months after symptom onset, and even after symptom resolution [5, 6, 9–15]. Importantly, detection of SARS-CoV-2 RNA by RT-PCR does not necessary mean shedding of infectious virus [16]. Given the high pressure on the health care system during the pandemic, it is important to establish to what extent hospitalized patients are contagious and how long they need to be isolated. Thus, it is essential to improve our understanding of factors important for potential SARS-CoV-2 viral transmission from patients.

Thus far, only a limited number of reports on shedding of infectious viruses from the airways in hospitalized COVID-19 patients have been published. In individuals with mild COVID-19, viable virus has been isolated up to 8 days [9]. Virus could not be isolated after 8 days in mild cases of COVID-19 despite high viral loads [9], nor from samples with less than 10^6 viral RNA copies/mL [17]. Moreover, the time point at which virus no longer could be isolated coincided with the detection of antibodies to SARS-CoV-2 in serum [18]. In general, antibody responses are detected in < 40% of the patients within the first week of symptoms, and by day 15 after onset of symptoms, a vast majority has seroconverted [19]. In a study with 253 patients, ranging from asymptomatic cases to severe cases at the intensive care unit, isolation of replicating SARS-CoV-2 from airway samples succeeded in 6% of the samples drawn at day 10 [20].

Methods
Aim
In order to better understand the viral transmissibility and the time needed to isolate hospitalized COVID-19 patients, we investigated if infectious SARS-CoV-2 could be cultured from nasopharyngeal and sputum samples in hospitalized COVID-19 patients later than 8 days after onset of symptoms. Further, we investigated if the absence of SARS-CoV-2-specific antibody responses in serum could predict shedding of infectious virus.

Sample collection
Patients admitted to the Department of Infectious Diseases or the Intensive Care Unit at Karolinska University Hospital, Stockholm, Sweden, with a symptom duration of > 8 days and with a previous SARS-CoV-2 RNA positive nasopharynx or pharynx sample, were included in the study. One patient, sampled 5 days after onset of symptoms, was included as a positive control for viral shedding.

Nasopharyngeal swabs (NPS), sputum as well as serum samples, were collected from all patients at one time point per patient during May 2020. Samples were stored at + 4 °C until transported to the laboratory where virus culture was initiated within 8 h after sampling. All NPS and sputum samples were analyzed by virus culturing and RT-PCR. Serum samples were analyzed by RT-PCR and for binding and neutralizing antibodies.

Ethical approval and consent to participate
The study was approved by the Swedish Ethical Review Authority, and all relevant regulations for work with human participants were complied with. Patient samples were obtained according to the Declaration of Helsinki. Patients included in the study provided written informed consent. For sedated patients, the denoted primary contact was asked to provide informed consent for the patients and if applicable subsequently informed consent by the patient was obtained.

RT-PCR
SARS-CoV-2 RT-PCR were performed on all collected patient samples (NPS, sputum and serum) as well as on supernatants from viral culture. 600 μl Trizol was added to each sample and RNA was subsequently extracted using PSS magLEAD 12gC. Following extraction, RT-PCR targeting the envelope(E)- and RNA dependent RNA polymerase (RdRp)-genes were used to detect the presence of SARS-CoV-2 RNA [21, 22]. A cycle threshold (CT) value above 40 was considered negative using a threshold of 0.1. Viral levels were not further quantified.

Isolation of live SARS-CoV-2 from patient material
Virus isolation was carried out at a biosafety level 3 (BSL3) laboratory. For the isolation of viable SARS-CoV-2 from patient samples, 100 μL NPS or 100 μL sputum were diluted with 100 μL Dulbecco’s Modified Eagle’s Medium (DMEM) and subsequently inoculated on Vero E6 (ATCC CRL 1586) cells in duplicate. Inoculation was carried out for 1.5 h at 37 °C and 5% CO2, then medium...
DMEM supplemented with 5% fetal bovine serum (FBS), 10X Antibiotic-Antimycotic, 0.6 µg/mL penicillin, 60 µg/mL streptomycin, 2 mM L-glutamine, 20 mM HEPES) were added. Cells were continuously monitored for cytopathic effect (CPE). After 10 days, the cultures were harvested and supernatants were analyzed with RT-PCR specific for the SARS-CoV-2 E-gene and RdRp-gene [21, 22]. Positive CPE, in parallel with increased levels of virus in the culture as analyzed by RT-PCR, was used to confirm the presence of live virus in the patient samples.

**Sequencing of SARS-CoV-2**

The primary clinical samples and samples from the 4 individuals with positive virus cultures were sequenced in order to confirm that the cultured virus originated from the primary sample. Sequencing libraries were constructed using the Ion AmpliSeq SARS-CoV-2 Research Panel (Thermo Fisher Scientific, MA, USA). cDNA was synthesized from SARS-CoV-2 RNA using SuperScript IV VILO Master Mix (Thermo Fisher Scientific, MA, USA) and incubated at 25 °C for 10 min, 50 °C for 10 min and 85 °C for 5 min. Automated library preparation and amplification was performed on an Ion Chef instrument with AmpliSeq Chef reagents and specific SARS-CoV-2 primers (Thermo Fisher Scientific, MA, USA). Libraries were quantified as previously published [23]. Libraries were normalized to a final concentration of 35 pM and prepared for sequencing with the Ion 540 Kit-Chef (Thermo Fisher Scientific, MA, USA) for 200 base-pair reads. Sequencing was performed on an Ion GeneStudio S5 Sequencing System (Thermo Fisher Scientific, MA, USA). Raw reads were trimmed and filtered using default parameters, then analyzed with the Ion Torrent Suite software plugin coverageAnalysis, where an average read coverage of 20x for every amplicon of a sample was required to pass quality control. Variant calling against the SARS-CoV-2 reference sequence (NC_045512.2) was performed by the Ion Torrent Suite software plugin variantCaller.

**Immunofluorescence assay (IFA)**

IFA was performed as previously described [22]. Briefly, SARS-CoV-2-infected Vero cells mixed with uninfected Vero cells were used as target cells. Serum samples were heat-inactivated at 56 °C for 30 min prior to analysis. Serum samples were two-fold serially diluted starting at 1:20. The titer of IgG in each serum sample was determined by the inverted dilution factor value for the highest dilution with positive staining with AF488-conjugated AffiniPure Goat Anti-Human IgG Ab (Jackson ImmunoResearch Laboratories).

**Micro-neutralization assay**

SARS-CoV-2 neutralization assay was performed as previously described [22]. Heat inactivated (56 °C for 30 min) serum were diluted in a two-fold dilution series starting from 1:10. Each sample was prepared in duplicates. Each dilution was mixed with an equal volume of 4000 TCID50/ml SARS-CoV-2. After incubation, 100 µL of the mixtures were added to Vero E6 cells on 96-well plates and incubated at 37 °C 5% CO2. Four days later the cells were inspected for signs of CPE by optical microscopy. Each well was scored as either ‘neutralizing’ if less than 50% of the cell layer showed signs of CPE, or ‘non-neutralizing’ if ≥50% CPE was observed.

**Statistics**

Statistical analyses were performed using GraphPad Prism software 7.0 for MacOSX (GraphPad Software). Correlation analyses were performed using Spearman’s correlation test.

**Results**

**Clinical characteristics**

Thirty-six hospitalized COVID-19 patients were enrolled in this study. The majority of the patients were men (n = 25, 69%), and the median age was 60.5 years (range 25–77 years) (Table 1). Most patients had an underlying risk factor for severe COVID-19 [24]; cardiovascular diseases, respiratory diseases and immunosuppression (Table 1). Thirty-three (92%) patients received supplemental oxygen treatment sometime during their hospitalization. Fourteen (39%) patients were treated in the intensive care unit, out of which 9 were treated with mechanical ventilation. Fourteen patients received immunomodulatory treatment, and two received remdesivir prior to inclusion in the study (Table 1). Patient samples were collected at a median of 18 days (range 9–53 days) after self-reported onset of symptoms, and at a median of 8 days (range 1–44 days) after positive SARS-CoV-2 diagnostic PCR test (Table 1).

**Detection of SARS-CoV-2 RNA in hospitalized COVID-19 patients**

Including all nasopharyngeal and sputum samples analyzed 23 (64%) of the 36 patients were positive in SARS-CoV-2 RT-PCR. Fourteen of the nasopharynx samples and 18 of the sputum samples were positive (Table 2).

The median time of sampling for the PCR-positive patient group was 16 days (range 10–54 days) after symptom onset and 8 days (range 1–44 days) after positive diagnostic sample (Table 2). Thirteen of the 36 patients were SARS-CoV-2 PCR-negative in both nasopharynx and sputum, they were sampled at a median of 22 days (range 11–38 days) after symptom onset and a median of
12 days (range 2–27 days) after positive diagnostic sample (Table 2).

SARS-CoV-2 RNA was detected by PCR in 39% of the nasopharynx samples (Fig. 1a), and in 60% of the sputum samples (Fig. 1b). SARS-CoV-2 RNA was detected for longer time after onset of symptom in the sputum samples as compared to the nasopharynx samples (Fig. 1). SARS-CoV-2 was isolated in culture from four patients, representing 11% of all patients, and 17% of the SARS-CoV-2 PCR-positive patients (Table 2, Fig. 1). The CT-values in the SARS-CoV-2 PCR for the samples from the culture positive patients ranged between 19 and 26 (Table 2), the CT-values for the samples from culture negative, but SARS-CoV-2 PCR positive patients ranged between 20 and 35 (Table 2). The primary samples as well as the culture samples from the 4 culture positive patients were sequenced. None of the viral samples showed any significant sequence deviation from the virus variants circulating in the country at that time (data not shown).

All four patients shedding infectious SARS-CoV-2 had underlying diseases, potentially increasing the risk of severe COVID-19 in accordance with [24]; such as underlying lung disease, cardiovascular diseases (hypertension), kidney failure, diabetes mellitus type II, BMI > 25 and hematological malignancy. Three out of the culture positive patients (ID 2, 3 and 4) had been symptomatic for 9–11 days before sampling, and 2 of these patients received betamethasone for less than 24 h before sampling. The fourth patient (ID 1), still had viable SARS-CoV-2 in both nasopharynx and sputa on day 16 after onset of symptoms. This patient was immunosuppressed due to a haematological malignancy with leukopenia during hospitalization and had received no COVID-19 treatment, except oxygen and anticoagulants. Three (8%) patients (ID 8, 17 and 22) had detectable but low levels of SARS-CoV-2 RNA in blood, however viable SARS-CoV-2 could not be isolated from respiratory samples of these patients (Table 2).

**SARS-CoV-2-specific antibody responses in hospitalized COVID-19 patients**

All but two patients (94%) had detectable levels of SARS-CoV-2-specific immunoglobulin G (IgG) in serum, with IFA-titers ranging from 1:40 to 1:2560. Neutralizing antibodies towards SARS-CoV-2 were detected in 33 of the 36 patients (92%). The three patients without neutralizing antibodies towards SARS-CoV-2 all secreted viable SARS-CoV-2 and the fourth patient secreting viable virus had a low neutralizing titer (1:10) (Table 2). As expected, the positive control patient, sampled at day 5 after onset of symptoms, was positive for infectious virus in the airways and had no detectable SARS-CoV-2-specific antibodies (data not shown).

We observed a strong positive correlation between total SARS-CoV-2-specific IgG titers and neutralizing antibody titers (Spearman’s correlation: rs = 0.719, p < 0.001) (Fig. 2a). Patients with SARS-CoV-2 IgG titers

---

**Table 1 COVID-19 patient characteristics (n = 36)**

| Cohort characteristics | no. | % |
|------------------------|-----|---|
| Male                   | 25  | 69|
| Age, years, median (range) | 60.5 (25–77) |   |
| Symptom onset to sampling, days, median (range) | 18 (9–53) |   |
| Days since diagnosis (positive SARS-CoV-2 PCR), median (range) | 8 (1–44) |   |

Comorbidities

| Condition                               | no. | % |
|-----------------------------------------|-----|---|
| Diabetes mellitus type II               | 13  | 36|
| Hypertension                            | 11  | 31|
| Lung disease                            | 8   | 22|
| Cardiovascular disease                  | 7   | 19|
| BMI > 25                                | 6   | 17|
| Malignancy                              | 3   | 8 |

Treatment

| Treatment                               | no. | % |
|-----------------------------------------|-----|---|
| Supplemental oxygen                     | 33  | 92|
| Mechanical ventilation                  | 9   | 25|
| ICU admission a                         | 14  | 39|
| Immunomodulatory drugs b                | 14  | 39|
| Antiviral treatment (remdesivir)        | 2   | 6 |

---

*aICU admission before study sampling (n = 11), ICU treatment during study sampling (n = 2), ICU treatment after study sampling (n = 1)*

*bTreatment before sampling corticosteroids (n = 13), tociluzimab (n = 2) or anakinra (n = 1). Two patients had prednisolone treatment before COVID-19 and had extra corticosteroids added as treatment*
equal to or below 1:40 either displayed no detectable, or low levels of neutralizing antibodies (Table 3, Fig. 1a). We also observed generally higher levels of SARS-CoV-2 IgG titers and neutralizing antibody titers in patients sampled late after symptom onset (Fig. 2b-c).
Discussion

Despite the ongoing SARS-CoV-2 pandemic, the understanding of the dynamics of viral shedding and antibody responses is still limited. We conducted a cross-sectional study on 36 hospitalized COVID-19 patients to assess potential contagiousness of the patients in a hospital setting during May 2020. We were able to isolate viable SARS-CoV-2 from four out of 23 PCR-positive patients. Three of the four patients with infectious/viable SARS-CoV-2 in the airways were sampled within 11 days after symptom onset. However, the fourth patient, who was immunocompromised at the time of inclusion, was sampled at day 16 after symptom onset, indicating that infectious/viable SARS-CoV-2 virus can be shed rather late during COVID-19 in immunocompromised patients. We were not able to detect viable SARS-CoV-2 virus from patients displaying SARS-CoV-2-specific IgG titers above 40, or neutralizing antibody titers above 10. Seroconversion, with detectable neutralizing antibodies, was observed in all 32 patients from whom no viable SARS-CoV-2 virus could be isolated from the respiratory tract. In addition, as expected, no infectious virus could be isolated from the patients that were SARS-CoV-2 RNA PCR negative. There was a large variation in total specific IgG and neutralizing antibody titers in patients sampled early after symptom onset, while patients sampled late after symptom onset (i.e. more than 20 days), showed similar antibody levels.

Our data suggest that individuals with low, or undetectable, levels of SARS-CoV-2 antibodies have an increased risk of shedding infectious virus. This is in concordance with a recent report, with 129 severely ill COVID-19 patients, where infectious virus was found for up to 20 days, median 8 days, after symptom onset [25]. Determinants for the detection of infectious SARS-CoV-2 in that study were either a viral load above 7 log10 RNA copies/mL in airways or a neutralizing antibody titer below 20 in serum [25]. Prior reports of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection also show similar data, where SARS-CoV-1 could be isolated during the first 2 weeks, but not after 22 days of illness [26]. In the context of SARS-CoV-2, multiple case reports with contradicting data have been published. For example, in one case report a patient was shedding infectious SARS-CoV-2 virus 18 days after symptom onset, despite seroconversion at day 10 and symptom resolution at day 9 [10]. To better understand the correlation between viral shedding and antibody

---

**Fig. 1** Distribution of positive and negative SARS-CoV-2 PCR samples over time after symptom onset. a Distribution of positive (upper row) and negative (lower row) SARS-CoV-2 PCR samples from nasopharynx. b Distribution of positive (upper row) and negative (lower row) SARS-CoV-2 PCR sputum samples. Red symbols indicate patients with nasopharynx/sputum samples from which infectious SARS-CoV-2 could be isolated.

**Fig. 2** SARS-CoV-2-specific antibody responses. a. Correlation between anti-SARS-CoV-2-specific IgG titers and neutralizing antibody titers. b. SARS-CoV-2-specific antibody titers over time since symptom onset. c. SARS-CoV-2-neutralizing antibody titers over time since symptom onset. Red symbols indicate patients with nasopharynx/sputum samples from which infectious SARS-CoV-2 could be isolated.
response in COVID-19 patients, large studies need to be performed with focus on the isolation of virus and not solely viral RNA detection. Additionally, case reports on re-infection of SARS-CoV-2 have been reported since the beginning of the pandemic [27], and reinfections with SARS-CoV-2 have been reported both from individuals with, as well as without, antibodies from previous SARS-CoV-2 infection [28–31]. In our study, we only show the development of neutralizing antibodies in the context of viral shedding in SARS-CoV-2 naïve patients. Thus, our results cannot be applied to patients with SARS-CoV-2 reinfection.

The World Health Organization (WHO) recommends at least 10 days after symptom onset plus an additional 3 days without fever and respiratory symptoms, before releasing COVID-19 patients from isolation regardless of isolation location or disease severity [32]. Except for in one immunocompromised patient with 16 days of symptoms, we could not detect infectious/viable SARS-CoV-2 later than 11 days of symptoms. This finding is in concordance with other studies detecting viable viruses long after symptom onset in immunocompromised patients [10, 11, 15, 33], where live virus has been detected for up to 61 days in patients with recently immunosuppression due to a hematological malignancy [34]. In the latter study patients with live virus > 20 days remained seronegative for antibodies to viral nucleoprotein, similar to our findings [34]. As our study took place during May 2020, which was prior to the emergence of the more recent virus variants of concern (e.g. B.1.1.7, P.1, B.1.351) [35–37], additional studies on shedding in patients infected with other variants of SARS-CoV-2 would be of interest.

We confirm a previous report [22] of a strong correlation between total SARS-CoV-2-specific IgG titers and neutralizing antibody titers. Our data also suggest that viable virus may only be present in airways from patients with low or undetectable SARS-CoV-2 antibody titers. Moreover, in the context of immunosuppressed patients cultures from respiratory samples might be necessary in conjunction with serology assays for SARS-CoV-2 antibodies to release the patient from isolation in a hospital setting, although conducting large scale culturing of virus from clinical samples is a challenge as it requires BSL3 laboratory as well as it is time and resource consuming.

**Conclusion**

Our data suggests that serological assays may help in providing guidance in judging if a RT-PCR patient may be shedding infectious SARS-CoV-2 virus or not, also in the case of immunocompromised COVID-19 patients.

**Abbreviations**

BMI: Body mass index; COVID-19: Coronavirus disease 2019; CPE: Cytopathic effect; CT value: Cycle threshold value; ICU: Intensive care unit; IFA: Immunofluorescence assay; IgG: Immunoglobulin G; NPS: Nasopharyngeal swabs; PCR: Polymerase chain reaction; RNA: Ribonucleic acid; RT-PCR: Real time - polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

**Acknowledgements**

The authors would like to thank the patients that contributed to the study. Further, authors would like to thank Karin Tegmark Wisell and Shamae Muradrasoli at the Public Health Agency of Sweden for contributing to the design of the study.

**Authors’ contributions**

H.G., S.G.R. and A.B. led the study. M.O., M.L.K., S.B., J.K., and A.B. designed experiments and optimized assays. H.G., S.F.J., R.F.J. and M.B. included patients and summarized clinical information. M.O., K.T.M., W.C, M.L.K., S.B., and J.K. performed experiments. H.G., S.G.R., M.O., S.F.J., R.V., W.C, K.T.M., M.L.K., S.B., N.J., A.F., A.S.S., J.K. and A.B. contributed to design and conceptualization of the study, discussed data analysis and interpreted the results. H.G. and S.G.R wrote the paper, with input provided by all co-authors. The author(s) read and approved the final manuscript.

**Table 3** SARS-CoV-2-specific antibody titers in relation to detectable SARS-CoV-2 RNA and infectious SARS-CoV-2 in nasopharynx in all COVID-19 patients (n = 36).

| Total SARS-CoV-2 IgG titer | Number of patients | PCR Positive no. | PCR negative no. | Culture positive no. | Culture negative no. |
|----------------------------|--------------------|------------------|-----------------|----------------------|----------------------|
| < 20                       | 2                  | 2 100            | 0 0             | 2 100                | 0 0                  |
| 20 to 40                   | 5                  | 3 60             | 2 40            | 2 40                 | 3 60                 |
| 160 to 320                 | 4                  | 3 75             | 1 25            | 0 0                  | 4 100                |
| 640 to 2560                | 25                 | 6 24             | 19 76           | 0 0                  | 25 100               |

| Neutralizing antibody titer | Number of patients | PCR Positive no. | PCR negative no. | Culture positive no. | Culture negative no. |
|----------------------------|--------------------|------------------|-----------------|----------------------|----------------------|
| < 10                       | 3                  | 3 100            | 0 0             | 3 100                | 0 0                  |
| 10 to 15                   | 5                  | 4 67             | 2 33            | 1 17                 | 5 83                 |
| 30 to 120                  | 18                 | 7 41             | 10 59           | 0 0                  | 17 100               |
| 160 to 580                 | 10                 | 0 0              | 10 100          | 0 0                  | 10 100               |

*a*neutralizing titer 10
Funding
Parts of this study was supported by Marianne and Marcus Wallenberg Foundation (SGR), grants provided by region Stockholm (ALF project) (SGR), grants from the Swedish Research Council (ASS, JR) and the Swedish Heart and Lung Foundation (ASS). Open Access funding provided by Karolinska Institute.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate
The study was approved by the Swedish Ethical Review Authority, and all relevant regulations for work with human participants were complied with. Patient samples were obtained according to the Declaration of Helsinki. Patients included in the study provided written informed consent. For sedated patients, the denoted primary contact was asked about the presumed will of the patient and if applicable subsequently consent by the patient.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Infectious Diseases, Karolinska University Hospital, SE-141 86 Stockholm, Sweden. 2Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 3Center for Infectious Medicine, Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden. 4Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 5Karolinska University Laboratory, Division of Transfusion Medicine and Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden. 6Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden. 7Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 8Department of Perinatal Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. 9Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Received: 26 December 2020 Accepted: 17 May 2021
Published online: 27 May 2021

References
1. WHO. Emergencies preparedness, response; Novel Coronavirus – China. https://www.who.int/csr/don/12-2020-january-2020-novel-coronavirus-china/en/.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and – 2020;58(1):7809:465–9. https://doi.org/10.1038/s41596-020-2196-x.
3. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. 2020;81(2):318–56. https://doi.org/10.1016/j.jinf.2020.03.054.
4. Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;77(6):748–54. https://doi.org/10.1016/j.eururo.2020.03.039.
5. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–74. https://doi.org/10.1016/S1473-3099(20)30196-1.
6. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;383(12):1177–9. https://doi.org/10.1056/NEJMoa2007377.
7. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5. https://doi.org/10.1038/s41591-020-0869-5.
8. Chen W, Hu Z, Yi C, Chi Y, Xiong Q, Tan CW, et al. An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report. J Biomed Res. 2020;46(4):470–4. https://doi.org/10.5555/JBR.34.20200099.
9. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020;25(3):210–5. https://doi.org/10.1016/j.idh.2020.05.002.
10. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–90. https://doi.org/10.1056/NEJMoa2008457.
11. Thevarajan I, Nguyen THQ, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–5. https://doi.org/10.1038/s41591-020-0819-2.
12. Zhao J, Yuan Q, Wang H, Liu W, Xiao L, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa244.
13. Singanayagam A, Patel M, Charett A, Bernal JL, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Eurosurveillance. 2020;25(23):2001483.
14. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKJ, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.
15. Varmaite R, Garcia M, Glans H, Maleki KT, Sandberg JT, Tynell J, et al. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. J Immunol (Baltimore, Md : 1950). 2020;205(5):4347–46.
16. Beser J, Hallström BM, Advani A, Andersson S, Östlund G, Winiecka-Krusnell J, et al. Improving the genotyping resolution of Cryptosporidium hominis subtype IbA10G2 using one step PCR-based amplicon sequencing. Infect Genet Evol. 2017;55:297–304. https://doi.org/10.1016/j.meegid.2017.08.035.
17. Wu Z, McGoojan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239–42. https://doi.org/10.1001/jama.2020.2648.
18. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021;12(1):267. https://doi.org/10.1038/s41467-020-20221-4.
19. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong I, et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis. 2004;10(2):294–9. https://doi.org/10.3201/eid1002.030610.
20. Dao TL, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis. 2020;1–13. https://doi.org/10.1007/s10096-020-04088-z.
28. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1275.

29. Zhou X, Zhou J, Zhao J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. BMC Infect Dis. 2020;20(1):1–4.

30. Torres DA, Ribeiro LCB, Riello APFL, Horovitz DDG, Pinto LFR, Croda J. Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: case report. J Med Virol. 2020. https://doi.org/10.1002/jmv.26637.

31. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020. https://doi.org/10.1016/S1473-3099(20)30764-7.

32. WHO. Criteria for releasing COVID-19 patients from isolation. https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-patients-from-isolation.

33. Ridgway JP, Shah NS, Robicsek AA. Prolonged shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA among patients with coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol. 2020;1–2. https://doi.org/10.1016/s0276-0464(20)30088-z.

34. Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586–8. https://doi.org/10.1056/NEJMc2031670.

35. Andrew Rambaut NL, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alessandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz, on behalf of COVID-19 Genomics Consortium UK (CoG-UK). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 2020. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.

36. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020.12.21.20248640. https://doi.org/10.1101/2020.12.21.2024864.

37. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science (New York, NY). 2021. https://doi.org/10.1126/science.abh2644.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.